N
Nexo Therapeutics
Uses a combination of covalent ligand discovery and chemical biology to develop new cancer therapies
About Nexo Therapeutics
Nexo Therapeutics is a biotechnology startup that operates in the pharmaceutical industry, specifically in the area of drug discovery. The company focuses on identifying and developing novel cancer therapies by targeting elusive drug targets that have been identified by biology but remain untapped due to the lack of quality ligands and limited understanding of the pharmacology required to effectively modulate these targets.
Read full description
Nexo Therapeutics serves a market that includes medical research institutions, pharmaceutical companies, and healthcare providers. Their clients are those seeking innovative solutions for cancer treatment, particularly therapies that can effectively target and modulate elusive drug targets.
The company's business model revolves around two purpose-built platforms for target biology and ligand discovery. They utilize small molecule control of chimeric proteins to gain insights into the depth and duration of target modulation needed to drive pharmacology. They also use protein structure and computation to optimize covalent hits into leads, matching the small molecule modality to target biology.
Nexo Therapeutics generates revenue through the discovery and development of novel cancer therapies. They also raise funds through series financing, as evidenced by their recent emergence from stealth with a $60 million Series A financing led by Versant Ventures, New Enterprise Associates, and Cormorant Asset Management.
In summary, Nexo Therapeutics is a promising startup in the biotechnology sector, leveraging innovative platforms and approaches to unlock a pipeline of novel cancer therapies.
At a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Watertown, United States
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 38.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jul 2023 | $60M | $240M | Versant Ventures · Cormorant Asset Management · NEA | ↗ |
Growth signals
Latest recorded traffic for Nexo Therapeutics is 1.1K monthly website visits, down 42.1% over the last three months. Nexo Therapeutics's team declined 5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nexo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nexo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.